CD276 and prostate cancer: Recently, numerous studies have shown that the expression of CD276 in prostate cancer, breast cancer, and other tumors is significantly up-regulated, and it is directly associated with tumor avoidance of the host immune response and the poor prognosis of these patients [3,4,5,6,29,30,31,32].